



October 4, 2024

**Notice Regarding Calculated 340B Ceiling Prices and Offers
of Refunds to 340B Covered Entities**

Ascend Laboratories, LLC (“Ascend”) has recently calculated 340B Ceiling Prices for the NDCs referenced below for the time period of June 1, 2023, through June 30, 2024. The need to calculate and submit 340B prices for this period were a result of a product family being relaunched after having been discontinued previously in 2019.

As a result of the calculated 340B Ceiling Prices, Ascend has determined that, pursuant to 42 U.S.C. §256b(d)(1)(B)(ii) and 42 C.F.R. § 10.11(b)(4), a refund may be owed to 340B Covered Entities that purchased any of the below NDCs during that time period. As a result of the calculated 340B Ceiling Prices, Ascend has determined that a refund may be owed to 340B Covered Entities that purchased any of the below NDC’s during the period of June 1, 2023, through June 30, 2024.

Ascend participates in the 340B program, has asked the Office of Pharmacy Affairs (“OPA”) to post this notice on OPA’s public website to ensure transparency to all 340B Covered Entities regarding the Ceiling Price calculations and to offer a refund to any of the 340B Covered Entities that may have purchased the products identified. Based on the calculation for the product(s) noted below.

If a Covered Entity believes they are due a refund, they should contact Ascend at 340brefund@ascendlaboratories.com, by March 31, 2025. Include in the subject line that this is a “340B Reimbursement” and include your entity’s 340B ID, and proof of purchase and make that request. Please include Invoice Date, Wholesaler Purchased from, Quantity Purchased, Invoiced Amount, and Purchase Invoice Number in the body of your email so that we can research your inquiry and reimburse, as necessary. Refunds will be issued as a check to a Covered Entity. Separate correspondence including a check and details of the payment will be sent to the 340B Covered Entity.



NDC	NDC Description	340B Sales Periods
67877-0537-07	Temozolomide 5mg Capsules - 5 C	Q2 2023 – Q1 2024
67877-0537-14	Temozolomide 5mg Capsules - 14 Ct	Q2 2023 – Q1 2024
67877-0538-07	Temozolomide 20mg Capsules - 5 Ct	Q2 2023 – Q1 2024
67877-0538-14	Temozolomide 20mg Capsules - 14 Ct	Q2 2023 – Q1 2024
67877-0539-07	Temozolomide 100mg Capsules - 5 Ct	Q2 2023 – Q1 2024
67877-0539-14	Temozolomide 100mg Capsules–14 Ct	Q2 2023 – Q1 2024
67877-0540-07	Temozolomide 140mg Capsules - 5 Ct	Q2 2023 – Q1 2024
67877-0540-14	Temozolomide 140mg Capsules - 14 Ct	Q2 2023 – Q1 2024
67877-0541-07	Temozolomide 180mg Capsules - 5 Ct	Q2 2023 – Q1 2024
67877-0541-14	Temozolomide 180mg Capsules – 14 Ct	Q2 2023 – Q1 2024
67877-0542-07	Temozolomide 250mg Capsules - 5 Ct	Q2 2023 – Q1 2024